Gastrointestinal Stromal Tumor Market Growth Outlook Through 2024-2033

Overview and Scope
A gastrointestinal stromal tumor (GIST) is a type of rare, non-epithelial tumor that originates in the gastrointestinal (GI) tract. These are most commonly developed in the stomach or the small intestine, but they can occur anywhere along the GI tract, from the esophagus to the rectum.

Sizing and Forecast
The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.18 billion in 2023 to $1.28 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased awareness and early diagnosis, emergence of targeted therapies, enhanced surgical techniques, development of personalized medicine, improvements in supportive care.

The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to continued research and drug development, rise in patient-centric healthcare, integration of precision medicine in clinical practice, increasing access to targeted therapies, expanding genomic profiling capabilities. Major trends in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, exploration of combination therapies.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Segmentation & Regional Insights
The gastrointestinal stromal tumor market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

North America was the largest region in the gastrointestinal stromal tumor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13248&type=smp

Major Driver Impacting Market Growth
The growing incidence of stomach cancer is expected to propel the growth of the gastrointestinal stromal tumor market going forward. Stomach cancer refers to the uncontrolled growth and multiplication of malignant cells in the lining of the stomach. while gastrointestinal stromal tumors (GISTs) can occur in the stomach, they are distinct from stomach cancer. When two separate tumors collide and merge into one, patients with GISTs have been found to have an increased risk of developing additional cancers, including small bowel adenocarcinoma. For instance, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of stomach cancer in the UK is projected to fall by 12% between 2023-2025 and 2038-2040, to 8 cases per 100,000 people on average each year. Therefore, the growing incidence of stomach cancer is driving the growth of the gastrointestinal stromal tumor market.

Key Industry Players

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

The gastrointestinal stromal tumor market report table of contents includes:

1. Executive Summary
2. Gastrointestinal Stromal Tumor Market Characteristics
3. Gastrointestinal Stromal Tumor Market Trends And Strategies
4. Gastrointestinal Stromal Tumor Market – Macro Economic Scenario
5. Global Gastrointestinal Stromal Tumor Market Size and Growth
.
.
.
31. Gastrointestinal Stromal Tumor Market Other Major And Innovative Companies
32. Global Gastrointestinal Stromal Tumor Market Competitive Benchmarking
33. Global Gastrointestinal Stromal Tumor Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gastrointestinal Stromal Tumor Market
35. Gastrointestinal Stromal Tumor Market Future Outlook and Potential Analysis
36.Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model